Melatonin and cardiac pathophysiology

Heart and Metabolism

Volumn , Issue 44, 2009, Pages 31-34

  Reiter, Russel J ^a   Tan, Dun X ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cardiac hypertrophy; Drug toxicity; Heart; Hypertension; Ischemia reperfusion injury; Melatonin

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE; CYCLOSPORIN A; DOXORUBICIN; EPIRUBICIN; MELATONIN; MELATONIN RECEPTOR; REACTIVE OXYGEN METABOLITE;

BLOOD PRESSURE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; HYPERTHYROIDISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 72449198415     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol. 1991;79:C153-C158.
2. Sanchez-Hidalgo M, de la Lastra CA, Carruscosa-Salmoral M, et al. Age-related changes in melatonin synthesis in rat extra-pineal tissues. Exp Gerontol. 2009;44:328-334.
3. Dubocovich ML, Markowska M. Functional MT1and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101-110.
4. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res. 2008;44:16-25.
5. Naji L, Carrillo-Vico A, Guerrero JM, Calvo JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci. 2004;74:2227-2236.
6. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res. 2007;42:28-42.
7. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res. 2008;45:235-246.
8. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007;42:319-322.
9. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci. 2005;76:1795-1803.
10. Ohkubo T, Imai Y, Tsuji I, et al. Relation between nocturnal decline in blood pressure and mortality: the Ohasama study. Am J Hypertens. 1997;10:1201-1207.
11. Sheer FAJL, van Montfrans GA, van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43:192-197.
12. Jou MJ, Peng TI, Yu PZ, et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res. 2007; 43:389-403.
13. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res. 2003;58:50-59.
14. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ, El-Sokkary GH. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res. 1998;25:184-191.
15. Lagneux C, Joyeux M, Demenge P, Ribuot C, Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in isolated rat heart. Life Sci. 2000;66:503-509.
16. Lee YM, Chen HR, Hsaio G, Sheu JR, Wang JJ, Yen MH. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res. 2002;33:72-80.
17. Dobsak P, Siegelova J, Eicher JC, et al. Melatonin protects against ischemia-reperfusion injury and inhibits apoptosis in isolated working rat heart. Pathophysiology. 2003;9:179-187.
18. Morishima I, Matsui H, Mukawa H, et al. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci. 1998;63:511-521.
19. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299-1321.
20. Dziegiel P, Jethon Z, Suder E, et al. Role of exogenous melatonin in reducing the cardiotoxic effects of daunorubicin and doxorubicin. Exp Toxicol Pathol. 2002;53:433-439.
21. Guven A, Yavuz O, Cam M, Ercan F, Bulsan N, Comunoglu C. Melatonin protects against epirubicin cardiotoxicity. Acta Histochem. 2007;109:52-60.
22. Rezzani R, Rodella LF, Bononini F, Tengattini S, Bianchi R, Reiter RJ. Beneficial effects of melatonin in protecting against cyclosporine A-induced cardiotoxicity are receptor medicated. J Pineal Res. 2006;41:288-295.
23. Rezzani R, Fraschini F, Gasco MR, et al. Melatonin delivery in solid nanoparticles: prevention of cyclosporine A induced cardiac changes. J Pineal Res. 2009;46:255-261.
24. Ghosh G, De K, Marty S, et al. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res. 2007;42:71-82.
25. Sallinen P, Saarela S, Ilves M, Vakkuri O, Leppäluoto J. The expression of MT1 and MT2 melatonin receptor mRNA in several rat tissues. Life Sci. 2005;76:1123-1134.